Zenocutuzumab is a bispecific antibody targeting HER2/HER3 developed by Merus NV. On July 7, 2023, the U.S. FDA granted Zenocutuzumab breakthrough therapy desig-nation for NRG1 fusion-positive non-small cell lung cancer.
This study first revealed that dexmedetomidine inhibits the microglial synaptic elimination process mediated by the complement C3-C3aR signaling pathway.
Synapse functions as an indispensable free drug pipeline database tool for pharmaceutical and biotech sectors, enhancing drug pipelines and marketed drugs by presenting analytical intelligence on a wide range of drug discovery and development.
Fruquintinib is a small molecule drug targeting VEGFR1, VEGFR2, and VEGFR3. This drug was initially developed by Hutchison Whampoa Medicine (Shanghai) Co., Ltd.
The study, titled "Netrin-1 blockade inhibits tumor growth and EMT features in endometrial cancer," presents compelling evidence of the efficacy of a novel anti-Netrin-1 antibody in reducing tumor progression and inhibiting epithelial-to-mesenchymal transition (EMT).
AMPK, which stands for AMP-activated protein kinase, is a key molecule in regulating energy metabolism and is at the core of research into diabetes and other metabolic-related diseases.